Title: Advances in the study on metformin beyond its hypoglycemic effect
Abstract: As a safe and effective antidiabetic drug , metformin has been considered to be the first line drug for the therapy of diabetes. With further research on metformin, it turns out that metformin can not only lower blood glucose but also display certain benefits for patients with polycystic ovary syndrome and nonalcoholic fatty liver disease, which is independent of the hypoglycemic effect of metformin. Furthermore, metformin can block cancer cells growth by activation of AMP-activated protein kinase and inhibition of mammalian target of rapamycin signaling pathway. In recent years, the effects of metformin on anti-atherosclerosis, endothelial function protection and other cardiovascular benefits have also become a research hotspot.
Publication Year: 2013
Publication Date: 2013-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot